中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (1): 5-15.doi: 10.35541/cjd.20220618
中华医学会皮肤性病学分会免疫学组
收稿日期:2022-09-02
修回日期:2022-10-31
发布日期:2023-01-03
通讯作者:
姚煦；顾恒
E-mail:dryao_xu@126.com; guheng@aliyun.com
Immunology Group, Chinese Society of Dermatology
Received:2022-09-02
Revised:2022-10-31
Published:2023-01-03
Contact:
Yao Xu; Gu Heng
E-mail:dryao_xu@126.com; guheng@aliyun.com
摘要： 【摘要】 特应性皮炎是常见的瘙痒性、慢性炎症性皮肤病，近20年来患病率迅速增加，在非致命性皮肤疾病负担中排名第一。临床上迫切需要开展行之有效的特应性皮炎全程管理。本共识根据特应性皮炎在预防、治疗、康复、照护等方面的特性，遵循既往指南和临床共识，制定了一整套管理方案，有望为我国特应性皮炎的全程管理提供科学参考。
中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023,56(1):5-15. doi:10.35541/cjd.20220618
Immunology Group, Chinese Society of Dermatology. Consensus on the whole-process management of atopic dermatitis[J]. Chinese Journal of Dermatology, 2023, 56(1): 5-15.doi:10.35541/cjd.20220618
| ［1］ | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000. |
| ［2］ | Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019［J］. World Allergy Organ J, 2021,14（11）:100604. doi: 10.1016/j.waojou.2021.100604. |
| ［3］ | Thyssen JP, Corn G, Wohlfahrt J, et al. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: a nationwide cohort study［J］. Clin Exp Allergy, 2019,49（11）:1455⁃1463. doi: 10.1111/cea.13487. |
| ［4］ | Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580. |
| ［5］ | Tsai TF, Rajagopalan M, Chu CY, et al. Burden of atopic dermatitis in Asia［J］. J Dermatol, 2019,46（10）:825⁃834. doi: 10.1111/1346⁃8138.15048. |
| ［6］ | Girolomoni G, de Bruin⁃Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis［J］. Ther Adv Chronic Dis, 2021,12:204062232 11002979. doi: 10.1177/204062 23211002979. |
| ［7］ | Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment［J］. Immunol Allergy Clin North Am, 2015,35（1）:161⁃183. doi: 10.1016/j.iac. 2014.09.008. |
| ［8］ | 李巍. 特应性皮炎与过敏进程［J］. 医学与哲学, 2014,35（6）:12⁃14. |
| ［9］ | 张洪明, 叶巍岭, 郭焱, 等. 监护人对儿童特应性皮炎认知情况的调查［J］. 中国麻风皮肤病杂志, 2013,29（9）:572⁃574. doi: 10.3969/j.issn.1009⁃1157.2013.09.010. |
| ［10］ | 田晶, 申春平, 马琳. 患者治疗教育在儿童特应性皮炎长期治疗管理中的作用［J］. 中国皮肤性病学杂志, 2016,30（7）:691⁃694. doi: 10.13735/j.cjdv.1001⁃7089.201511102. |
| ［11］ | Capozza K, Schwartz A. Does it work and is it safe? Parents′ perspectives on adherence to medication for atopic dermatitis［J］. Pediatr Dermatol, 2020,37（1）:58⁃61. doi: 10.1111/pde. 13991. |
| ［12］ | Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2717⁃2744. doi: 10. 1111/jdv.16892. |
| ［13］ | 高莹, 邓维. 儿童特应性皮炎的诊断及鉴别诊断［J］. 中国医刊, 2020,55（10）:1061⁃1064. doi: 10.3969/j.issn.1008⁃1070. 2020.10.005. |
| ［14］ | 姚煦. 常用特应性皮炎严重度评估方法［J］. 中华皮肤科杂志, 2021,54（6）:539⁃541. doi: 10.35541/cjd.20200825. |
| ［15］ | 宋志强, 王欢. 特应性皮炎的治疗进展: 新药物、新手段、新模式［J］. 中华皮肤科杂志, 2021,54（2）:161⁃164. doi: 10.35541/cjd.20201028. |
| ［16］ | 梁云生, 余艺昕, 杨斌. 系统抗炎是重度免疫性皮肤病达标治疗的关键［J］. 中华医学杂志, 2021,101（16）:1119⁃1122. doi: 10.3760/cma.j.cn112137⁃20201209⁃03313. |
| ［17］ | 顾于蓓, 李玥. 炎症性肠病达标治疗面临的优势与困境［J］. 中华炎性肠病杂志, 2018,（2）:124⁃126. doi: 10.3760/cma.j.issn.2096⁃367X.2018.02.012. |
| ［18］ | Smith S, Baker C, Gebauer K, et al. Atopic dermatitis in adults: an Australian management consensus［J］. Australas J Dermatol, 2020,61（1）:23⁃32. doi: 10.1111/ajd.13124. |
| ［19］ | Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review［J］. Dermatol Ther （Heidelb）, 2017,7（1）:1⁃23. doi: 10.1007/s13555⁃016⁃0170⁃1. |
| ［20］ | De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751. |
| ［21］ | 赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（08）:855⁃864. doi:10.13735/j.cjdv.1001⁃7089.202205115. |
| ［22］ | Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis⁃⁃an emerging concept［J］. Allergy, 2009,64（2）:276⁃278. doi: 10. 1111/j.1398⁃9995.2008.01803.x. |
| ［23］ | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833. |
| ［24］ | Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment⁃related patient needs in atopic eczema: insights for personalized goal orientation［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:142⁃152. doi: 10.1111/jdv.15919. |
| ［25］ | 王珊, 何黎, 王华, 等. 功效性护肤品在儿童特应性皮炎中的应用指南［J］. 中国皮肤性病学杂志, 2020,34（9）:977⁃981. doi: 10.13735/j.cjdv.1001⁃7089.202006019. |
| ［26］ | 中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识（2017版）［J］. 中华皮肤科杂志, 2017,50（11）:784⁃789. doi: 10.3760/cma.j.issn.0412⁃4030.2017.11.002. |
| ［27］ | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组. 特应性皮炎湿包疗法临床应用专家共识［J］. 中华皮肤科杂志, 2022,55（4）:289⁃294. doi: 10.35541/cjd.20210823. |
| ［28］ | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part II［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv. 14888. |
| ［29］ | Davari DR, Nieman EL, McShane DB, et al. Current perspectives on the systemic management of atopic dermatitis［J］. J Asthma Allergy, 2021,14:595⁃607. doi: 10.2147/JAA.S287638. |
| ［30］ | Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema［J］. Ann Dermatol, 2012,24（3）:253⁃260. doi: 10.5021/ad.2012.24.3.253. |
| ［31］ | Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption［J］. Am J Ther, 2009,16（3）:264⁃273. doi: 10.1097/MJT.0b013e31818a975c. |
| ［32］ | Chittock J, Brown K, Cork MJ, et al. Comparing the effect of a twice⁃weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis［J］. Acta Derm Venereol, 2015,95（6）:653⁃658. doi: 10.2340/00015 555⁃2048. |
| ［33］ | Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment［J］. Allergy, 2008,63（6）:742⁃750. doi: 10.1111/j.1398⁃9995.2008. 01683.x. |
| ［34］ | Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study［J］. Br J Dermatol, 2008,159（6）:1348⁃1356. doi: 10.1111/j.1365⁃2133.2008.08813.x. |
| ［35］ | Berth⁃Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study［J］. BMJ, 2003,326（7403）:1367. doi: 10.1136/bmj.326.7403.1367. |
| ［36］ | Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double⁃blind, controlled study［J］. Br J Dermatol, 2008,158（4）:801⁃807. doi: 10.1111/j.1365⁃2133.2008.08436.x. |
| ［37］ | Merola JF, Sidbury R, Wollenberg A, et al. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52⁃week randomized controlled phase 3 trial［J］. J Am Acad Dermatol, 2021,84（2）:495⁃497. doi: 10.1016/j.jaad.2020.05.003. |
| ［38］ | Ferreira S, Torres T. Dupilumab para el tratamiento de la dermatitis atópica［J］. Actas Dermo⁃Sifiliográficas, 2018,109（3）:230⁃240. doi: 10.1016/j.ad.2017.10.012. |
| ［39］ | Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis［J］. Am J Clin Dermatol, 2022,23（3）:393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0. |
| ［40］ | 田晶, 马琳. 特应性皮炎患者教育［J］. 中国医学文摘（皮肤科学）, 2016,33（02）:201⁃205. |
| ［41］ | LeBovidge JS, Elverson W, Timmons KG, et al. Multidisciplinary interventions in the management of atopic dermatitis［J］. J Allergy Clin Immunol, 2016,138（2）:325⁃334. doi: 10.1016/j.jaci.2016.04.003. |
| ［42］ | van Os⁃Medendorp H, Koffijberg H, Eland⁃de Kok PC, et al. E⁃health in caring for patients with atopic dermatitis: a randomized controlled cost⁃effectiveness study of internet⁃guided monitoring and online self⁃management training［J］. Br J Dermatol, 2012,166（5）:1060⁃1068. doi: 10.1111/j.1365⁃2133.2012.10829.x. |
| ［43］ | Winslow A, Keet CA. Preventing allergies through the skin［J］. Ann Allergy Asthma Immunol, 2022,129（3）:276⁃285. doi: 10. 1016/j.anai.2022.04.013. |
| ［44］ | Lowe AJ, Leung D, Tang M, et al. The skin as a target for prevention of the atopic march［J］. Ann Allergy Asthma Immunol, 2018,120（2）:145⁃151. doi: 10.1016/j.anai.2017.11.023. |
| ［45］ | Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention［J］. J Allergy Clin Immunol, 2014,134（4）:818⁃823. doi: 10.1016/j.jaci.2014.08.005. |
| ［46］ | Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis［J］. J Allergy Clin Immunol, 2014,134（4）:824⁃830.e6. doi: 10. 1016/j.jaci.2014.07.060. |
| ［47］ | Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial［J］. Lancet, 2020,395（10228）:962⁃972. doi: 10. 1016/S0140⁃6736（19）32984⁃8. |
| ［48］ | Sindher S, Alkotob SS, Shojinaga MN, et al. Pilot study measuring transepidermal water loss （TEWL） in children suggests trilipid cream is more effective than a paraffin⁃based emollient［J］. Allergy, 2020,75（10）:2662⁃2664. doi: 10.1111/all.14275. |
| ［49］ | Skjerven HO, Lie A, Vettukattil R, et al. Early food intervention and skin emollients to prevent food allergy in young children （PreventADALL）: a factorial, multicentre, cluster⁃randomised trial［J］. Lancet, 2022,399（10344）:2398⁃2411. doi: 10.1016/S0140⁃6736（22）00687⁃0. |
| ［50］ | Allen KJ, Koplin JJ, Ponsonby AL, et al. Vitamin D insufficiency is associated with challenge⁃proven food allergy in infants［J］. J Allergy Clin Immunol, 2013,131（4）:1109⁃1116, 1116.e1⁃6. doi: 10.1016/j.jaci.2013.01.017. |
| ［51］ | Hennessy Á, Hourihane JO, Malvisi L, et al. Antenatal vitamin D exposure and childhood eczema, food allergy, asthma and allergic rhinitis at 2 and 5 years of age in the atopic disease⁃specific Cork BASELINE Birth Cohort Study［J］. Allergy, 2018,73（11）:2182⁃2191. doi: 10.1111/all.13590. |
| ［52］ | Tsiaras WG, Weinstock MA. Factors influencing vitamin D status［J］. Acta Derm Venereol, 2011,91（2）:115⁃124. doi: 10.2340/00015555⁃0980. |
| ［53］ | Kim G, Bae JH. Vitamin D and atopic dermatitis: a systematic review and meta⁃analysis［J］. Nutrition, 2016,32（9）:913⁃920. doi: 10.1016/j.nut.2016.01.023. |
| ［54］ | Korpela K, Helve O, Kolho KL, et al. Maternal fecal microbiota transplantation in cesarean⁃born infants rapidly restores normal gut microbial development: a proof⁃of⁃concept study［J］. Cell, 2020,183（2）:324⁃334.e5. doi: 10.1016/j.cell.2020.08.047. |
| ［55］ | Wilson BC, Butler ÉM, Grigg CP, et al. Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: a pilot randomised placebo⁃controlled trial［J］. EBioMedicine, 2021,69:103443. doi: 10.1016/j.ebiom.2021.103443. |
| ［56］ | Cuello⁃Garcia CA, Brożek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta⁃analysis of randomized controlled trials［J］. J Allergy Clin Immunol, 2015,136（4）:952⁃961. doi: 10.1016/j.jaci.2015.04.031. |
| ［57］ | Garcia⁃Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta⁃analysis［J］. PLoS Med, 2018,15（2）:e1002507. doi: 10.1371/journal.pmed.1002507. |
| [1] | 洪芷榆 谢红付 李吉 黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128. |
| [2] | 中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业组. A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识[J]. 中华皮肤科杂志, 2023, 56(1): 16-21. |
| [3] | 李巍 李政. 【开放获取】典型与非典型表现的特应性皮炎[J]. 中华皮肤科杂志, 2023, 56(1): 1-4. |
| [4] | 高子蕊 赵培 窦沅青 刘萍 张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565. |
| [5] | 中华医学会皮肤性病学分会特应性皮炎研究中心 中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470. |
| [6] | 黄馨 陈筱昀 李亚萍 梁兴堃 张桂英 周英 湛意 罗帅寒天 廖洁月 肖嵘 龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493. |
| [7] | 陆晓云 张曾云鸥 肖风丽. 上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J]. 中华皮肤科杂志, 2022, 55(6): 548-551. |
| [8] | 徐西光 卢彬 孙建方. 表现为特应性皮炎样皮损的X连锁无丙种球蛋白血症1例[J]. 中华皮肤科杂志, 2022, 55(6): 536-537. |
| [9] | 孙晓丽 李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451. |
| [10] | 申晨 陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445. |
| [11] | 余愫 郁天泽 李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365. |
| [12] | 覃诗纯 李梦杰 陆晓云 肖风丽. 特应性皮炎的转录组学研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 365-369. |
| [13] | 李巍 尹慧彬. 特应性皮炎的部位异质性[J]. 中华皮肤科杂志, 2022, 55(4): 349-352. |
| [14] | 李妍 李明 徐薇 李邻峰. 【开放获取】凯普斯泰冷敷凝胶治疗成人轻中度特应性皮炎的随机双盲对照研究[J]. 中华皮肤科杂志, 2022, 55(4): 345-348. |
| [15] | 何素玲 田歆 梁景耀 邵蕾 李俊龙 黄琼霄 刘玉梅 王建琴. 重度特应性皮炎患者急性期和缓解期皮肤微生态研究[J]. 中华皮肤科杂志, 2022, 55(4): 329-336. |
|
